Form 4: Director Kristine Peterson Granted ENTA Stock Options

Enanta Pharmaceuticals Director Kristine Peterson was granted 20,000 stock options with an exercise price of $14.17, vesting over one year.

Summary

• Kristine Peterson, a Director of Enanta Pharmaceuticals Inc. (ENTA), was granted 20,000 stock options.
• The stock options have an exercise price of $14.17 per share.
• The options were granted on March 11, 2026, and will expire on March 11, 2036.
• The options will vest monthly in substantially equal installments over one year, beginning from the grant date.
• The final monthly installment will vest no later than the nearest trading day on the Nasdaq Global Select Market preceding the 2027 annual meeting of stockholders.
• Following this transaction, Kristine Peterson beneficially owns 20,000 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it represents a standard compensation practice that aligns a director's financial interests with the long-term performance of the company's stock.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders, incentivizing long-term company performance.

Future Outlook

The stock options are subject to a one-year monthly vesting schedule, indicating a future alignment of the director's compensation with the company's stock performance over that period.

Industry Context

StockSavvy.ai notes that the granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of compensation packages designed to attract and retain talent while aligning leadership incentives with shareholder value creation.

Comparison to Industry Standards

• StockSavvy.ai notes that option grants are a standard compensation practice across various industries, including pharmaceuticals, to align director interests with shareholder value. The specific number of options and exercise price would typically be benchmarked against peer companies of similar size and stage, though this filing does not provide such comparative data.

Stakeholder Impact

• Shareholders may benefit from the increased alignment of the director's interests with the company's stock performance, potentially leading to more value-driven decisions.

Next Steps

• The granted stock options will vest monthly over one year, with the final installment vesting before the 2027 annual meeting of stockholders.

Key Dates

Keywords

Enanta Pharmaceuticals, ENTA, Stock Options, Insider Transaction, Director Compensation, Form 4, Equity Grant